- Home
- TME vs INCY Comparison
TME vs INCY Comparison
Compare TME & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TME | INCY |
|---|---|---|
| Founded | N/A | 1991 |
| Country | China | United States |
| Employees | 5690 | N/A |
| Industry | Broadcasting | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 17.0B |
| IPO Year | N/A | 1994 |
Fundamental Metrics
Financial Performance| Metric | TME | INCY |
|---|---|---|
| Price | $9.11 | $117.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 21 |
| Target Price | $19.44 | ★ $103.52 |
| AVG Volume (30 Days) | ★ 7.4M | 1.7M |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | N/A | ★ 1.47 |
| Revenue | N/A | ★ $3,394,635,000.00 |
| Revenue This Year | $10.73 | $10.44 |
| Revenue Next Year | $10.19 | $10.99 |
| P/E Ratio | ★ $15.69 | $79.38 |
| Revenue Growth | N/A | ★ 13.67 |
| 52 Week Low | $7.94 | $67.17 |
| 52 Week High | $26.70 | $118.97 |
Technical Indicators
Market Signals| Indicator | TME | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | 64.56 |
| Support Level | $8.85 | $98.50 |
| Resistance Level | $9.80 | $118.97 |
| Average True Range (ATR) | 0.25 | 3.02 |
| MACD | 0.08 | -0.25 |
| Stochastic Oscillator | 62.90 | 78.21 |
Price Performance
Historical ComparisonAbout TME Tencent Music Entertainment Group each representing two
Tencent Music is the largest online music streaming platform in China, established in 2016 through the merger of QQ Music, Kuwo Music, and Kugou Music. Tencent, its largest shareholder, holds over 50% of the shares and more than 90% of the voting rights. Beyond streaming services, Tencent Music generates revenue through a diverse range of offerings, including podcasts, livestreaming, concerts, and karaoke.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.